
    
      Study Stage: Phase II/III Study Population Female patients with breast cancer will be
      enrolled to receive at least 4 cycles of TC chemotherapy, that is: Docetaxel 75 mg/m2 and
      Cyclophosphamide 600 mg/m2.

      Study Design: A multi-center, randomized, open-label, active-controlled phase II/III clinical
      trial
    
  